Health Rounds: Semaglutide pill Rybelsus matches heart benefits of injectable versions
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and ...
Novo Nordisk readies to bring weight-loss drug Wegovy to India
Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to ...
PharmExec5d
Rybelsus Found to Significantly Reduce Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes, Cardiovascular Disease
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
Managed Healthcare Executive8d
Rybelsus Reduces Cardiovascular Risk by 14% in New Trial | ACC 2025
Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...
Fierce Pharma6d
FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
CNBC on MSN8d
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
Reuters5d
Health Rounds: Semaglutide pill Rybelsus matches heart benefits of injectable versions
April 2 (Reuters) - (To receive the full newsletter in your inbox for free sign up here) Novo Nordisk’s (NOVOb.CO), opens new tab diabetes medicine Rybelsus, an oral form of the GLP-1 drug ...
BioSpace6d
Novo Paints Murky Cardio Picture for Semaglutide Franchise
According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...
Becker's Hospital Review6d
Rybelsus reduces cardiovascular event risk in late stage trial: Study
Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...